UNCTAD Forum: Local Drug Manufacturing A Key To Universal Health Coverage 16/10/2014 by Catherine Saez, Intellectual Property Watch Leave a Comment Local production of medicines in developing countries is key to advancing universal health coverage, but other factors need to be considered, such as the involvement of all stakeholders and policy coherence in governments, according to speakers attending the World Investment Forum this week. Several speakers called for a paradigm shift in global health.
At WTO, Experts Discuss Solutions To Drugs Innovation Crisis; IP Not In The List 03/10/2014 by Catherine Saez, Intellectual Property Watch 1 Comment The Universities Allied for Essential Medicines (UAEM) organised a panel at the World Trade Organization Public Forum this week on new approaches in university management of intellectual property. The panel gathered a diverse panel of experts giving their take on possible solutions to less innovation and higher prices of drugs, and the role of publicly-funded research.
Health Advocates Demand U-Turn In EU Trade Policy To Align With Its Health Objectives 29/09/2014 by Catherine Saez, Intellectual Property Watch Leave a Comment Health Action International Europe, and Oxfam today issued a briefing paper entitled, “Trading Away Access to Medicines: How the European trade agenda continues to undermine access to medicines.” The paper argues that new concerns such as the ebola virus and the threat of unchecked antimicrobial resistance show the need for a new model for financing pharmaceutical research and development.
Patent Landscape For Hepatitis Issued By WHO 26/09/2014 by Intellectual Property Watch Leave a Comment The World Health Organization has published an analysis of the patent situation for new hepatitis treatments, and a call for possible pharmaceutical products for prequalification.
Panellists Discuss Value Of Patent Pooling For HIV/AIDS, Potential For Other Diseases 25/09/2014 by William New, Intellectual Property Watch 1 Comment A side event to this week’s World Intellectual Property Organization annual General Assembly highlighted the work of the Geneva-based Medicines Patent Pool in fighting HIV/AIDS, and discussed whether it makes sense for the patent pool model to be extended to other diseases.
Gilead Monopoly Prevails Over Non-Discriminatory Access As Debated Hepatitis C Deal Sets Off 25/09/2014 by Intellectual Property Watch 2 Comments Gilead on 15 September struck voluntary licence deals with seven India-based generic manufacturers to expand access to its hepatitis C innovative drugs in developing countries. With a limited territory covered, this, yet deserving, pact raises doubts about the coherence of Indian counterparts at a time when there are no relevant patents in India, several pre-grant oppositions have been filed and unrestrained competition by compulsory licences could have been pursued, writes Daniele Dionisio.
Guest Post: Nine Mandatory Licences Allow Greater Access To Medicines In Ecuador 12/09/2014 by Intellectual Property Watch, Intellectual Property Watch 1 Comment What is a mandatory licence? Mandatory licenses are a legal remedy within the intellectual property flexibilities provided by the World Trade Organization allowing a government to grant permission to third parties to produce a patented product or use a patented process without the consent of the patentee, in order to address a priority status for the country.
WHO: Fight Ebola Now, Solve Patent Issues Later 06/09/2014 by Catherine Saez, Intellectual Property Watch 2 Comments The world and the global health community have been taken by surprise by the worst outbreak of Ebola so far. The World Health Organization today (5 September) said a vaccine could be available in November 2014 if proven safe. So far, according to the WHO, intellectual property issues have not acted as a barrier to accessing potential treatments and vaccines, and the focus for now is on emergency measures to find health solutions.
WHO Health Specialists Meeting To Evaluate Potential Ebola Therapies and Vaccines 03/09/2014 by Catherine Saez, Intellectual Property Watch 1 Comment The World Health Organization this week is holding a consultation on potential Ebola therapies and vaccines.
Biosimilar Medicines Need Strong Regulation, IP Crucial For Innovation, Pharma Says 29/08/2014 by Catherine Saez, Intellectual Property Watch Leave a Comment Biosimilar medicines might prove to be a new reservoir for innovation for the pharmaceutical industry. However, the complexity of their manufacture needs a stringent regulatory framework, according to the industry.